Last reviewed · How we verify
Betmiga®
Betmiba works by increasing the levels of magnesium in the urine, which helps to prevent kidney stones.
Betmiba works by increasing the levels of magnesium in the urine, which helps to prevent kidney stones. Used for Prevention of kidney stones.
At a glance
| Generic name | Betmiga® |
|---|---|
| Also known as | YM178, Mirabegron, Myrbetriq®, Betanis® |
| Sponsor | Astellas Pharma Europe Ltd. |
| Drug class | Potassium-sparing diuretic |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 2 |
Mechanism of action
Betmiba increases the levels of magnesium in the urine by inhibiting the reabsorption of magnesium in the kidneys. This helps to prevent the formation of kidney stones by increasing the concentration of magnesium in the urine, which can help to dissolve and prevent the growth of stones.
Approved indications
- Prevention of kidney stones
Common side effects
- Hypokalemia
- Hyperkalemia
- Dizziness
- Fatigue
- Nausea
Key clinical trials
- Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis (EARLY_PHASE1)
- Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity (PHASE4)
- A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
- A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
- Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron (EARLY_PHASE1)
- A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) (PHASE4)
- Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation (PHASE2)
- Specified Drug Use-results Survey of Betanis Tablets
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betmiga® CI brief — competitive landscape report
- Betmiga® updates RSS · CI watch RSS
- Astellas Pharma Europe Ltd. portfolio CI